Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Caterpillar Inc (CAT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Caterpillar Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Caterpillar Inc trades at $943.88 (market cap $438.67B). The key difference: Caterpillar Inc is far larger — about 11× Alnylam Pharmaceuticals, Inc.'s market cap, and Caterpillar Inc pays a 0.68% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CAT | |
|---|---|---|
Market Cap | $39.89B | $438.67B |
Sector | Health | Industrials |
52-Week High | $491.22 | $1.06K |
52-Week Low | $278.09 | $404.64 |
Enterprise Value | $38.15B | $477.67B |
Dividend Yield | — | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Caterpillar (CAT) trades at $952.41, up 1.49% with strong year-to-date momentum driven by AI infrastructure demand. The stock shows bullish technical positioning above key support levels, while fundamentals reveal robust profitability with 13.33% net margins and 51.35% ROE. Recent earnings beats and a $10.2B generator segment from data centers highlight growth catalysts, though elevated valuations (P/E 47.43) warrant caution.
Outlook remains positive with analyst consensus targeting $1,010 (6% upside), supported by 32 consecutive dividend increases and AI-driven backlog growth. Key risks include cyclical exposure, debt levels at 43.94% of assets, and geopolitical sensitivity. Institutional sentiment leans bullish with 55% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Caterpillar Inc
Caterpillar Inc. designs, manufactures, and markets construction, mining, and forestry machinery. The Company also manufactures engines and other related parts for its equipment, and offers financing and insurance. Caterpillar distributes its products through a worldwide organization of dealers.
Read more on CAT →
